Found: 92
Select item for more details and to access through your institution.
Molecular profiling and analysis of genetic aberrations aimed at identifying potential therapeutic targets in fibrolamellar carcinoma of the liver.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Immune checkpoint inhibitors for hepatocellular carcinoma.
- Published in:
- 2019
- By:
- Publication type:
- journal article
Hepatocellular adenoma among adult survivors of childhood and young adult cancer.
- Published in:
- 2017
- By:
- Publication type:
- journal article
A phase 1/1B trial of ADI-PEG 20 plus nab-paclitaxel and gemcitabine in patients with advanced pancreatic adenocarcinoma.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Pharmacokinetics and safety of vismodegib in patients with advanced solid malignancies and hepatic impairment.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Skin necrosis induced by generic enoxaparin.
- Published in:
- American Journal of Hematology, 2013, v. 88, n. 4, p. 339, doi. 10.1002/ajh.23401
- By:
- Publication type:
- Article
PHOCUS: A Phase 3, Randomized, Open-Label Study of Sequential Treatment with Pexa-Vec (JX-594) and Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2024, v. 13, n. 3, p. 256, doi. 10.1159/000533650
- By:
- Publication type:
- Article
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial.
- Published in:
- Liver Cancer (2235-1795), 2023, v. 12, n. 1, p. 72, doi. 10.1159/000527175
- By:
- Publication type:
- Article
First-In-Human Effects of PPT1 Inhibition Using the Oral Treatment with GNS561/Ezurpimtrostat in Patients with Primary and Secondary Liver Cancers.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 3, p. 268, doi. 10.1159/000522418
- By:
- Publication type:
- Article
Outcomes Based on Plasma Biomarkers for the Phase 3 CELESTIAL Trial of Cabozantinib versus Placebo in Advanced Hepatocellular Carcinoma.
- Published in:
- Liver Cancer (2235-1795), 2022, v. 11, n. 1, p. 38, doi. 10.1159/000519867
- By:
- Publication type:
- Article
Comparative Efficacy of Atezolizumab plus Bevacizumab and Other Treatment Options for Patients with Unresectable Hepatocellular Carcinoma: A Network Meta-Analysis.
- Published in:
- Liver Cancer (2235-1795), 2021, v. 10, n. 3, p. 240, doi. 10.1159/000515302
- By:
- Publication type:
- Article
Expanding the treatment options for hepatocellular carcinoma: combining transarterial chemoembolization with radiofrequency ablation.
- Published in:
- 2008
- By:
- Publication type:
- commentary
Expanding the Treatment Options for Hepatocellular Carcinoma.
- Published in:
- 2008
- By:
- Publication type:
- Editorial
SYSTEMIC THERAPIES FOR HEPATOCELLULAR CARCINOMA.
- Published in:
- Lebanese Medical Journal, 2010, v. 58, p. S28
- By:
- Publication type:
- Article
SYSTEMIC THERAPY AND NOVEL AGENTS IN THE TREATMENT OF PANCREAS CANCER.
- Published in:
- Lebanese Medical Journal, 2010, v. 58, p. S20
- By:
- Publication type:
- Article
TRIAGING AND CALL MANAGEMENT IN ONCOLOGY NURSING.
- Published in:
- Lebanese Medical Journal, 2010, v. 58, p. S66
- By:
- Publication type:
- Article
NURSING MANAGEMENT OF HAND-FOOT SYNDROME AND HAND-FOOT SKIN REACTION.
- Published in:
- Lebanese Medical Journal, 2010, v. 58, p. S63
- By:
- Publication type:
- Article
Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
- Published in:
- 2018
- By:
- Publication type:
- journal article
Doxorubicin Plus Sorafenib in Treatment of Advanced Hepatocellular Carcinoma.
- Published in:
- 2011
- By:
- Publication type:
- Letter
The impact of new data in the treatment of advanced hepatocellular carcinoma.
- Published in:
- Current Oncology Reports, 2008, v. 10, n. 3, p. 199, doi. 10.1007/s11912-008-0031-x
- By:
- Publication type:
- Article
Radiation and Immune Checkpoint Inhibitors: Combination Therapy for Treatment of Hepatocellular Carcinoma.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 23, p. 16773, doi. 10.3390/ijms242316773
- By:
- Publication type:
- Article
Predictive Biomarkers for Immune-Checkpoint Inhibitor Treatment Response in Patients with Hepatocellular Carcinoma.
- Published in:
- International Journal of Molecular Sciences, 2023, v. 24, n. 8, p. 7640, doi. 10.3390/ijms24087640
- By:
- Publication type:
- Article
Recurrence of Hepatocellular Carcinoma After Complete Radiologic Response to Trans-Arterial Embolization: A Retrospective Study on Patterns, Treatments, and Prognoses.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2022, v. 29, n. 11, p. 6815, doi. 10.1245/s10434-022-12036-8
- By:
- Publication type:
- Article
Safety and Efficacy of Hepatic Artery Embolization in Heavily Treated Patients with Intrahepatic Cholangiocarcinoma: Analysis of Clinicopathological and Radiographic Parameters Associated with Better Overall Survival.
- Published in:
- Current Oncology, 2023, v. 30, n. 10, p. 9181, doi. 10.3390/curroncol30100663
- By:
- Publication type:
- Article
Efficacy and safety of cabozantinib for patients with advanced hepatocellular carcinoma based on albumin-bilirubin grade.
- Published in:
- 2022
- By:
- Publication type:
- journal article
Comparative Efficacy of Cabozantinib and Regorafenib for Advanced Hepatocellular Carcinoma.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Comprehensive multiplatform biomarker analysis of 350 hepatocellular carcinomas identifies potential novel therapeutic options.
- Published in:
- Journal of Surgical Oncology, 2016, v. 113, n. 1, p. 55, doi. 10.1002/jso.24086
- By:
- Publication type:
- Article
Defining incidence and complications of fibrolamellar liver cancer through tiered computational analysis of clinical data.
- Published in:
- NPJ Precision Oncology, 2023, v. 7, n. 1, p. 1, doi. 10.1038/s41698-023-00371-2
- By:
- Publication type:
- Article
MEK Inhibitor-Associated Ocular Hypertension.
- Published in:
- Ocular Oncology & Pathology, 2024, v. 10, n. 2, p. 98, doi. 10.1159/000535427
- By:
- Publication type:
- Article
Prospective Evaluation of Germline Alterations in Patients With Exocrine Pancreatic Neoplasms.
- Published in:
- 2018
- By:
- Publication type:
- journal article
Factors affecting outcomes of Yttrium-90 radioembolization in heavily pretreated patients with intrahepatic cholangiocarcinoma.
- Published in:
- Abdominal Radiology, 2023, v. 48, n. 7, p. 2434, doi. 10.1007/s00261-023-03930-0
- By:
- Publication type:
- Article
Dermatologic Adverse Events Associated with Selective Fibroblast Growth Factor Receptor Inhibitors: Overview, Prevention, and Management Guidelines.
- Published in:
- Oncologist, 2021, v. 26, n. 2, p. e316, doi. 10.1002/onco.13552
- By:
- Publication type:
- Article
Phase Ib Study of Enzalutamide with or Without Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 12, p. e1825, doi. 10.1634/theoncologist.2020-0521
- By:
- Publication type:
- Article
Phase II Multicenter, Open‐Label Study of Oral ENMD‐2076 for the Treatment of Patients with Advanced Fibrolamellar Carcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 12, p. e1837, doi. 10.1634/theoncologist.2020-0093
- By:
- Publication type:
- Article
A Multicenter Randomized Three‐Arm Phase II Study of (1) Everolimus, (2) Estrogen Deprivation Therapy (EDT) with Leuprolide + Letrozole, and (3) Everolimus + EDT in Patients with Unresectable Fibrolamellar Carcinoma.
- Published in:
- Oncologist, 2020, v. 25, n. 11, p. 925, doi. 10.1634/theoncologist.2020-0367
- By:
- Publication type:
- Article
An Open‐Label, Multicenter, Phase I, Dose Escalation Study with Phase II Expansion Cohort to Determine the Safety, Pharmacokinetics, and Preliminary Antitumor Activity of Intravenous TKM‐080301 in Subjects with Advanced Hepatocellular Carcinoma
- Published in:
- Oncologist, 2019, v. 24, n. 6, p. 747, doi. 10.1634/theoncologist.2018-0838
- By:
- Publication type:
- Article
A Phase Ib, Open‐Label Study of Dalantercept, an Activin Receptor‐Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma.
- Published in:
- Oncologist, 2019, v. 24, n. 2, p. 161, doi. 10.1634/theoncologist.2018-0654
- By:
- Publication type:
- Article
Phase II Study of First-Line Trebananib Plus Sorafenib in Patients with Advanced Hepatocellular Carcinoma.
- Published in:
- Oncologist, 2017, v. 22, n. 7, p. 780, doi. 10.1634/theoncologist.2017-0058
- By:
- Publication type:
- Article
A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603)
- Published in:
- 2010
- By:
- Publication type:
- Journal Article
A Cancer and Leukemia Group B Phase II Study of Sunitinib Malate in Patients with Previously Treated Metastatic Pancreatic Adenocarcinoma (CALGB 80603).
- Published in:
- Oncologist, 2010, v. 15, n. 12, p. 1310, doi. 10.1634/theoncologist.2010-0152
- By:
- Publication type:
- Article
Commentary: Sorafenib--The End of a Long Journey in Search of Systemic Therapy for Hepatocellular Carcinoma, or the Beginning?
- Published in:
- 2009
- By:
- Publication type:
- Editorial
Phase II trial of sorafenib and doxorubicin in patients with advanced hepatocellular carcinoma after disease progression on sorafenib.
- Published in:
- Cancer Medicine, 2020, v. 9, n. 20, p. 7453, doi. 10.1002/cam4.3389
- By:
- Publication type:
- Article
Association between posttreatment α‐fetoprotein reduction and outcomes in real‐world US patients with advanced hepatocellular carcinoma.
- Published in:
- Cancer (0008543X), 2023, v. 129, n. 13, p. 2064, doi. 10.1002/cncr.34754
- By:
- Publication type:
- Article
Circulating tumor and invasive cell expression profiling predicts effective therapy in pancreatic cancer.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 15, p. 2958, doi. 10.1002/cncr.34269
- By:
- Publication type:
- Article
Equipoise, drug development, and biliary cancer.
- Published in:
- Cancer (0008543X), 2022, v. 128, n. 5, p. 944, doi. 10.1002/cncr.34020
- By:
- Publication type:
- Article
Pancreas cancer and BRCA: A critical subset of patients with improving therapeutic outcomes.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 23, p. 4393, doi. 10.1002/cncr.33812
- By:
- Publication type:
- Article
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
- Published in:
- Cancer (0008543X), 2020, v. 126, n. 9, p. 1995, doi. 10.1002/cncr.32740
- By:
- Publication type:
- Article
Germline alterations in patients with biliary tract cancers: A spectrum of significant and previously underappreciated findings.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Regional differences in gallbladder cancer pathogenesis: Insights from a multi-institutional comparison of tumor mutations.
- Published in:
- 2019
- By:
- Publication type:
- journal article